545 related articles for article (PubMed ID: 11996686)
21. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.
Swenson DL; Warfield KL; Negley DL; Schmaljohn A; Aman MJ; Bavari S
Vaccine; 2005 Apr; 23(23):3033-42. PubMed ID: 15811650
[TBL] [Abstract][Full Text] [Related]
22. Ebola virus: from discovery to vaccine.
Feldmann H; Jones S; Klenk HD; Schnittler HJ
Nat Rev Immunol; 2003 Aug; 3(8):677-85. PubMed ID: 12974482
[TBL] [Abstract][Full Text] [Related]
23. Development of a preventive vaccine for Ebola virus infection in primates.
Sullivan NJ; Sanchez A; Rollin PE; Yang ZY; Nabel GJ
Nature; 2000 Nov; 408(6812):605-9. PubMed ID: 11117750
[TBL] [Abstract][Full Text] [Related]
24. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
25. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
26. A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge.
Domi A; Feldmann F; Basu R; McCurley N; Shifflett K; Emanuel J; Hellerstein MS; Guirakhoo F; Orlandi C; Flinko R; Lewis GK; Hanley PW; Feldmann H; Robinson HL; Marzi A
Sci Rep; 2018 Jan; 8(1):864. PubMed ID: 29339750
[TBL] [Abstract][Full Text] [Related]
27. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
[TBL] [Abstract][Full Text] [Related]
28. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
Geisbert TW; Geisbert JB; Leung A; Daddario-DiCaprio KM; Hensley LE; Grolla A; Feldmann H
J Virol; 2009 Jul; 83(14):7296-304. PubMed ID: 19386702
[TBL] [Abstract][Full Text] [Related]
29. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
mBio; 2019 May; 10(3):. PubMed ID: 31138743
[TBL] [Abstract][Full Text] [Related]
30. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.
Meyer M; Garron T; Lubaki NM; Mire CE; Fenton KA; Klages C; Olinger GG; Geisbert TW; Collins PL; Bukreyev A
J Clin Invest; 2015 Aug; 125(8):3241-55. PubMed ID: 26168222
[TBL] [Abstract][Full Text] [Related]
31. Towards a vaccine against Ebola virus.
Geisbert TW; Jahrling PB
Expert Rev Vaccines; 2003 Dec; 2(6):777-89. PubMed ID: 14711361
[TBL] [Abstract][Full Text] [Related]
32. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.
Wong G; Qiu X
Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134
[TBL] [Abstract][Full Text] [Related]
33. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP
Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432
[TBL] [Abstract][Full Text] [Related]
34. Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.
Geisbert TW; Strong JE; Feldmann H
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S91-7. PubMed ID: 26063223
[TBL] [Abstract][Full Text] [Related]
35. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
[TBL] [Abstract][Full Text] [Related]
36. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.
Olinger GG; Bailey MA; Dye JM; Bakken R; Kuehne A; Kondig J; Wilson J; Hogan RJ; Hart MK
J Virol; 2005 Nov; 79(22):14189-96. PubMed ID: 16254354
[TBL] [Abstract][Full Text] [Related]
37. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
[TBL] [Abstract][Full Text] [Related]
38. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660.
Johnston RE; Johnson PR; Connell MJ; Montefiori DC; West A; Collier ML; Cecil C; Swanstrom R; Frelinger JA; Davis NL
Vaccine; 2005 Oct; 23(42):4969-79. PubMed ID: 16005121
[TBL] [Abstract][Full Text] [Related]
39. A single shot against Ebola and Marburg virus.
Baize S
Nat Med; 2005 Jul; 11(7):720-1. PubMed ID: 16015361
[No Abstract] [Full Text] [Related]
40. Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.
Wang H; Wong G; Zhu W; He S; Zhao Y; Yan F; Rahim MN; Bi Y; Zhang Z; Cheng K; Jin H; Cao Z; Zheng X; Gai W; Bai J; Chen W; Zou Y; Gao Y; Gao GF; Yang S; Xia X; Qiu X
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
